During the recent session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s traded shares were 0.56 million, with the beta value of the company hitting -0.54. At the last check today, the stock’s price was $3.93, reflecting an intraday gain of 8.86% or $0.32. The 52-week high for the AMLX share is $19.18, that puts it down -388.04 from that peak though still a striking 59.8% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $348.20M, and the average trade volume was 834.02K shares over the past three months.
Amylyx Pharmaceuticals Inc (AMLX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. AMLX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.55.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Amylyx Pharmaceuticals Inc (AMLX) registered a 8.86% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.86% in intraday trading to $3.93, hitting a weekly high. The stock’s 5-day price performance is 19.82%, and it has moved by 6.50% in 30 days. Based on these gigs, the overall price performance for the year is -79.15%.
The consensus price target of analysts on Wall Street is $9, which implies an increase of 56.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $11 respectively. As a result, AMLX is trading at a discount of -179.9% off the target high and -1.78% off the low.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 88.64M and -1.02M respectively. In this case, analysts expect current quarter sales to shrink by -100.00% and then jump by 100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -78.71%. While earnings are projected to return 54.70% in 2025, the next five years will return 25.21% per annum.
AMLX Dividends
Amylyx Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
The next largest institutional holding, with 3.34 million shares, is of AQR CAPITAL MANAGEMENT LLC’s that is approximately 4.9114% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.35 million.
Also, the Mutual Funds coming in first place with the largest holdings of Amylyx Pharmaceuticals Inc (AMLX) shares are Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.81 shares. This amounts to just over 2.04 percent of the company’s overall shares, with a $7.06 million market value. The same data shows that the other fund manager holds slightly less at 1.2, or about 1.35% of the stock, which is worth about $4.66 million.
